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ABSTRACT
Objectives: The success rate of methotrexate (MTX) therapy varies among tubal ectopic pregnancies. Common 
methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T&A1298C) have been suggested to alter MTX effect. 
This study aimed to assess and compare MTX treatment failure rates with respect to MTHFR polymorphisms in trophoblasts 
of ectopic tubal pregnancies. 
Material and methods: A retrospective chart review of tubal ectopic pregnancies was conducted and 34 eligible cases 
were found. Paraffinized blocks of ectopic trophoblastic tissues were retrieved from the archives of pathology department. 
Common MTHFR polymorphisms were studied on microdissected trophoblastic tissues. Sixteen cases with history of failed 
MTX therapy (study group) and 18 control cases were compared for their pertinent clinical characteristics and common 
MTHFR polymorphisms (C677T&A1298) data.
Results: In the study group, there were 8 (50%) C677T single nucleotide polymorphisms (SNP) and 9 (56.7%) A1298C SNP. 
Polymorphism rates were not found to be different between two groups for neither polymorphism (p > 0.05 for both). 
Number of compound heterozygotes was 3 (18.7%) in study group and 5 (27.7%) in controls (p = 0.693). In addition, MTHFR 
polymorphism presence seemed to have no effect on interval serum β-hCG concentration change in MTX-fail group (p=0.693).
Conclusions: Our data implied that common MTHFR polymorphisms of ectopic trophoblastic tissue are not associated 
with MTX failure in patients with tubal pregnancies. Additionally, serum β-hCG concentration changes caused by MTX 
treatment and studied MTHFR polymorphisms are likely independent. 
Key words: tubal pregnancy, methotrexate, methylenetetrahydrofolate reductase, polymorphism, trophoblast
Ginekologia Polska 2018; 89, 10: 536–540
INTRODUCTION
Ectopic pregnancy is a significant health problem. 
Although it is difficult to estimate, its incidence is about 
1.5% in all pregnancies and approximately 0.3 maternal 
deaths occur per 100.000 live births [1, 2]. Increased risk 
for other ectopic pregnancies and fallopian tube damage 
are common morbidities of this condition. Early diagnosis 
reduces its morbidity and mortality. 
Medical treatment with methotrexate (MTX) is 
a suitable alternative to surgery in many cases. MTX acts 
as a folate antagonist and shows its anti-mitotic activity 
primarily in tissues with high proliferative capacity such as 
chorionic villi. It binds to dihydrofolate reductase enzyme 
irreversibly and inhibits the formation of reduced folate. 
Methylene-tetrahydrofolate reductase (MTHFR) is a well-
studied enzyme with a specific function of converting 
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5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate 
in homocysteine and methionine metabolism [3]. Since 
MTHFR involves in folate metabolism and MTX acts as 
a folate antagonist, efficacy of MTX in patients with MTHFR 
gene polymorphisms has been an area of interest [4, 5]. 
In this regard, certain polymorphisms in this gene have 
been shown to alter MTHFR enzyme’s catalytic activity. 
Namely, A1298C and C677T polymorphisms are common 
single nucleotide changes in the MTHFR gene at position 
1298 from adenine to cytosine and at position 677 from 
cytosine to thymine, respectively. These changes, especially 
homozygous alterations at C677T (TT genotype) have been 
shown to decrease its functional capacity [6]. Thus, there 
have been many studies on MTHFR gene polymorphisms 
and their association with several health conditions ranging 
from rheumatoid arthritis to cancers [5, 7-10]. 
Although it is widely used in the treatment of ectopic 
pregnancy, clinical response to MTX may vary even in 
carefully selected cases. Therefore, we aimed to investigate 
the possible association between common MTHFR 
polymorphisms (A1298 and C677T) and MTX treatment 
failure in patients with tubal pregnancies. Recently, this 
relation was not found on the blood samples of tubal 
ectopic pregnancies that have been treated with MTX [11]. 
In the present study, we focused on trophoblasts, rather 
than maternal blood samples in order to delineate possible 
fetal polymorphism effect.
MATERIAL AND METHODS
Patients
This was a retrospective study conducted at 
Adnan Menderes University Hospital, Aydin- Turkey. Local 
ethics committee approval was obtained for the study. 
Medical records of patients who underwent surgery for 
tubal ectopic pregnancy in the last three years (from March 
2014 to March 2017) have been screened. Charts of 40 cases 
were retrieved. These patients were divided into two 
groups based on their history of MTX treatment. Patients 
who had received MTX treatment but underwent surgery 
later for incomplete response were included into “study 
group”. Since it was not possible to obtain tubal samples 
from patients who had been successfully treated with MTX, 
surgically treated tubal ectopic pregnancies without prior 
MTX exposure were chosen as control group. Inclusion 
criteria for the study group were failed MTX treatment 
(either less than 15% drop of serum β-hCG levels between 
the 4th and 7th day of MTX protocol or clinical/laboratory 
signs of tubal rupture) and having surgical treatment 
afterwards. Control group comprised of cases that have 
not matched the following MTX treatment criteria, therefore 
underwent surgery for treatment without MTX trial: serum 
β-hCG level < 5.000 mIU/mL, adnexal mass diameter 
less than 35 mm measured by transvaginal ultrasound, 
hemodynamic stability, no history of hypersensitivity to 
MTX, no history of renal, liver, pulmonary or gastrointestinal 
disorders, normal laboratory values (no leucopenia or 
pancytopenia, normal transaminase, blood urea nitrogen 
and creatinine levels) [12]. Exclusion criteria for both groups 
were cesarean scar pregnancy, interstitial ectopic pregnancy 
and cervical pregnancy. All patients in the study group had 
single dose MTX protocol (50 mg/m2, intramuscular).
Microdissection of Tubal Samples
Hematoxylin and eosin (H&E) stained slides of tubal 
ectopic pregnancies were reviewed and areas of interest 
with chorionic villi were marked via fine-point permanent 
marker under light microscope (Olympus BX53, Olympus 
Co., Tokyo, Japan). Formalin fixed-paraffin embedded 
(FFPE) tissue blocks those belong to the marked slides 
were retrieved from the archives of pathology department. 
They were held in -200 C for 20 minutes and 6 μm thin 
sections were obtained via microtome (Thermo Shandon 
HM 430 Sliding Microtome, Thermo Fisher Scientific Inc., MA, 
USA). Wrinkling of the sections during microtome cutting 
were straightened in 450C water bath for 5 minutes and 
placed on separate slides. After processing in xylene and 
ethanol series for dewaxination and dehydration, slides 
were air dried. By matching these deparaffinized sections 
with previously marked H&E stained sections, areas of 
interest having chorionic villi were re-located. These regions 
were then carefully dissected under the light microscope 
at X40 magnification by means of pointed surgical blade 
[13]. Micro-dissected tissue samples were transferred and 
into separate microcentrifuge tubes (Eppendorf 1.5 mL 
microcentrifuge tubes, Merck KGaA, Darmstadt, Germany).
DNA Extraction and SNP Genotyping
DNA extraction from FFPE samples was achieved with 
a commercially available kit according to the manufacturer’s 
protocol user instructions (NucleoSpin DNA FFPE XS, 
MACHEREY-NAGEL GmbH&Co KG, Germany). Each sample 
was diluted in 100 µl distilled water. Following this procedure, 
single point mutation analyses for MTHFR C677T and A1298C 
were performed via SNP biotech Real-time PCR kit (SNP 
Biotechnology Research, Development and Production 
Ltd., Co., Turkey). Briefly, 20 µl wild-type (normal) and 20 µl 
mutant master-mix placed into individual tubes. Then 5µl of 
extracted DNA was added to each tube and Real-time PCR 
(QPCR) process was started. Conditions were; 950 C for 10 min, 
at 950C for the Hot Start for 15 seconds, 600 C for 1 minute and 
30 cycles (Thermal Cycler CFX96 Real-Time PCR equipment, 
BioRad, USA). HEX dye was used as controller. Assessments 
were then done by using carboxyfluorescein (FAM) dye 
labeled MTHFR 677 and 1298 polymorphism probes.
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Statistics
Statistical analysis was performed using SPSS (Statistical 
Package for the Social sciences) version 18 for Windows (SPSS 
Inc., Chicago, IL). The Kolmogorov-Smirnov test was used to 
assess the normality of numeric variables. For the numeric 
variables that were normally distributed, comparison 
between two groups was made by independent sample t test 
and descriptive statistics are presented as mean ± standard 
deviation. For the numeric variables that were not normally 
distributed, comparison between two groups was made 
by Mann–Whitney U test and descriptive statistics are 
presented as median (interquartile range). To analyze the 
categorical data, a chi-square test was used, and descriptive 
statistics are presented as frequency (%). The p values below 
0.05 were considered statistically significant.
RESULTS
Out of 40 cases that were retrieved from the medical 
records, two of them were excluded for cesarean scar 
pregnancy and one for interstitial pregnancy. Three cases 
were excluded for missing pertinent medical information. 
A total of 34 cases were left for final analysis. Among them, 
16 (47%) cases had surgical intervention due to failed 
MTX treatment (study group). Remaining 18 (53%) cases 
had surgery without prior MTX treatment (control group). 
Table 1. Clinic and demographic data comparison
Study Group
(MTX-Fail) (n = 16)
Controls
(n = 18) p
Age [years] 30.5 ± 5.2 32.7 ± 5.8 0.266
Parity* 1 (0-3) 1 (2) 0.495
BMI 25.7 ± 5.9 29.1 ± 8.4 0.320
Previous ectopic 
pregnancy, n [%] 4 (25) 2 (13.3) 0.654
Previous cesarean, n [%] 7 (56.2) 4 (43.8) 1.0
Previous endometrial 
curettage, n [%] 2 (12.5) 5 (33.3) 0.220
Gestational Age [days] 43.3 ± 9.1 49.2 ± 7.0 0.092
MTX to surgery interval 
[days] 10.0 ± 5.1 N/A N/A
Change in β-hCG 
concentration after 
MTX, [mIU/mL]**
C677T, wild type 603.5 (111.7–1281.0) N/A 0.645
C677T, mutant 180.0 (-151.2–2491.2) 1.0
A1298C, wild type 679.0 (1.0–827.0)
A1298C, mutant 299.0 (37.0–1615.5)
Hemoglobin level at 
hospitalization [g/dl] 12.1 ± 1.2 12.0 ±1.8 0.847
BMI — body mass index; MTX — methotrexate; N/A — not available; * data is 
given as median and interquartile range; **data is given as median and 25th 
–75th percentile
Table 2. Comparison of allele frequencies between groups
MTHFR
C677T
Study Group
n [%]
Controls
n [%] Total p
C 21 (65.62) 24 (66.66) 45 (66.17)
1.000T 11 (34.37) 12 (33.33) 23 (33.82)
Total 32 (100) 36 (100) 68 (100)
MTHFR
A1298C p
A 21 (65.62) 21 (58.33) 42 (61.76)
0.961C 11 (34.37) 15 (41.66) 26 (38.23)
Total 32 (100) 36 (100) 68 (100)
MTHFR — Methylenetetrahydrofolate reductase
Table 3. MTHFR genotype frequency comparison between groups
MTHFR C677T Study Groupn [%]
Control Group
n [%] p
Wild Type (CC) 8 (50) 8 (44.44)
0.538Heterozygote (CT) 5 (31.25) 8 (44.44)
Homozygote (TT) 3 (18.75) 2 (11.11)
Total 16 (100) 18 (100)
MTHFR A1298C
Wild type (AA) 7 (43.75) 7 (38.88)
0.731Heterozygote (AC) 7(43.75) 7 (38.88)
Homozygote (CC) 2 (12.5) 4 (22.22)
Total 16 (100) 18 (100)
COMPOUND HETEROZYGOTES
C677T /A1298C 3 (18.75) 5 (27.77) 0.693
MTHFR — Methylenetetrahydrofolate reductase
Clinical characteristics and demographic data of study and 
control group were presented in Table 1.
MTHFR genotypes C677T and A1298C were identified 
in all DNA samples extracted from FFPE sections of micro-
dissected tubal ectopic chorionic villi. All results including 
genotype and allele frequencies were shown in tables with 
their corresponding p values (Tab. 2 and 3). 
When polymorphisms were compared between 
study and control groups, no significant differences were 
found (p > 0.05). In this comparison, both homozygous 
and heterozygous genotypes were taken into account. 
There were 2 homozygote A1298C polymorphism (CC) 
carriers in the study group and 4 in the control group. 
C677T homozygosity (TT) was seen in three cases in study 
group, and in two cases in control group. As for compound 
heterozygosity (having both polymorphisms), there were 
three (18.7%) cases in the study group and 5 (27.7%) cases 
among controls. Number of patients who were compound 
heterozygotes were not different between groups either 
(p = 0.693).
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The differences between two β-hCG levels (on the 
day of MTX was administered and on the operation day) 
with respect to polymorphism statuses were measured in 
the study group to further evaluate MTX treatment and 
polymorphism relations. No significant differences were 
observed in β-hCG concentration change between patients 
with and without polymorphisms (p = 1.0 for A1298C and 
p = 0.645 for C677T, Tab. 1).
DISCUSSION
Ectopic pregnancy is still a common health problem 
with limited treatment options. MTX is the main therapeutic 
agent that is currently used when medical treatment is 
an option. It has an acceptable rate of success, especially in 
the early phases of trophoblast invasion. However, failures 
with MTX treatment are not rare [14]. The established MTX 
treatment indication criteria in tubal ectopic pregnancies 
are well defined to maximize its effectiveness and safety 
[12]. Also, according to a recent meta-analysis, there is no 
difference between single dose and multiple dose regimens 
in terms of success rates [15]. Therefore, it is reasonable 
to look for other factors such as individual genotypic 
differences that can influence the MTX treatment success 
in tubal ectopic pregnancies. 
Certain single nucleotide changes in MTHFR gene have 
been suggested to affect clinical response to MTX in variety 
of clinical situations such as in rheumatoid arthritis and 
childhood acute lymphoblastic lymphoma [4, 5]. Limited 
number of studies have investigated this effect in ectopic 
and molar pregnancies. By systemic administration, MTX 
reaches trophoblastic tissue via maternal circulation and 
shows its antimetabolite/antiproliferative action on rapidly 
proliferating trophoblasts. For that reason, we worked on 
fetal trophoblastic tissues rather than maternal blood 
samples to investigate the relation between common 
MTHFR polymorphisms and MTX treatment failure.
The results of this study indicated that MTHFR A1298C 
and C677T polymorphisms are not associated with MTX 
treatment failure in tubal ectopic pregnancies. In a similar 
study by Kutuk et. al., no significant differences in MTHFR 
polymorphism frequencies were reported between 21 MTX-
unresponsive and 88 responsive patients [11]. They also 
obtained paternal blood samples to infer fetal genotype 
and did not found any association either. 
Qu et al. investigated the similar hypothesis on 62 patients 
with low-risk gestational trophoblastic neoplasia. They 
analyzed molar tissues for same MTHFR polymorphisms 
and concluded that C677T homozygote mutation (TT) 
was associated with ineffective MTX treatment in this 
group of patients [16]. However, another study found no 
association between common MTHFR polymorphisms and 
clinical response to MTX therapy, when they genotyped the 
blood and molar tissue samples of gestational trophoblastic 
neoplasia cases [17]. Our results in ectopic trophoblastic 
tissue supported this finding even though study population 
and dose of MTX differed from theirs.
We also compared the interval change in serum β-hCG 
levels (from the day of MTX administration to day of surgery) 
between patients with MTHFR polymorphisms and those 
without. There was no difference in interval β-hCG levels 
between groups. Naturally, this parameter was observed 
only in the study group, since control group had no MTX 
exposure. This finding also implies that MTHFR A1298C and 
C677T polymorphisms of fetal trophoblastic tissue have no 
effect on MTX treatment efficacy. However, there are studies 
reporting increased efficacy of MTX in the presence of these 
polymorphisms in rheumatoid arthritis patients [18, 19].
In terms of population’s background MTHFR 
polymorphism frequencies, a previous large Turkish study 
reported the frequencies for C677T, C677C, T677T as 42%, 
47%, 9%, respectively and for A1298C, A1298A, C1298C as 
43%, 46%, 10%, respectively [20]. Only the frequency of 
homozygous C1298C SNP in our control group was found 
higher than the expected background frequency (22% 
vs. 10%).
One of the possible drawbacks of our study might be the 
use of manual technique rather than laser microdissection 
for sampling from FFPE tissues to minimize tissue 
contamination. Nevertheless, manual microdissection 
technique is a universally accepted method among 
pathologists for retrieving the area of interest for further 
molecular testing [13]. Furthermore, a previous study has 
genotyped MTHFR gene from maternal and paternal blood 
samples to infer ectopic trophoblasts’ genotype and their 
results were similar to ours. Other disadvantage of our study 
was the technical and ethical impossibility of trophoblastic 
tissue sampling from the patients whom had successful MTX 
treatment. Thus, for control group, we collected the records 
of patients with ectopic pregnancy without MTX exposure. 
Nevertheless, it could be assumed that approximately 90% 
of the control group patients would have been successfully 
treated by MTX, since majority of studies have reported such 
high success rates in eligible cases [21–24].
For similar future MTHFR polymorphism studies 
in ectopic pregnancies, paternal screening along with 
maternal screening would be valuable. Moreover, serum 
folate, homocysteine and vitamin B12 level measurements 
in a much larger population treated and not treated with 
MTX might add significant implications [11, 25–27]
CONCLUSIONS
In conclusion, our results suggest that common MTHFR 
polymorphisms in trophoblasts and MTX treatment failure 
in tubal ectopic pregnancies are probably not related. 
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Furthermore, these polymorphisms may not affect MTX 
related serum β-hCG concentrations. 
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